A Phase 4 interventional study of Risperidone 3 mg and Paliperidone Palmitate 50 mg eq. in Schizophrenia, sponsored by Janssen-Cilag International NV. Completed at 5 sites in Rwanda. Open to participants aged 19 Years to 34 Years. Per ClinicalTrials.gov, last updated 2025-04-27.
Sponsored by Janssen-Cilag International NV (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 127 studies testing risperidone in Schizophrenia — 4 open to participants now, 4 under way, 2 of them phase 3. Risperidone · Schizophrenia.
Among the 127 studies testing risperidone in Schizophrenia, this one is the 69th largest by enrollment of the 123 interventional ones that give a count, is one of 4 that started in 2021, is one of 63 in phase 4, and was the 122nd registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →4 of the 127 studies testing risperidone in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:
Minerva Neurosciences · Sites in United States
Ages 18–55
Northwell Health · Sites in United States, Canada
Ages 18–35
Louisiana State University Health Sciences Center Shreveport · Sites in United States
Ages 18–65
Centre for Addiction and Mental Health · Sites in Canada
Ages 18+
By country, each count listing its studies:
Risperidone: first FDA approval 1993 (RISPERDAL), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 19 Years to 34 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
127 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 7 · Phase 3 34 · Phase 4 63
First in 1996; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 93 is above the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 100 across the 123 interventional studies. Of the 106 that completed or were terminated, 30 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
63 of 127 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen-Cilag International NV, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen-Cilag International NV is the lead sponsor of 67 studies on the registry; none are open to participants now.
206 studies in Schizophrenia by Johnson & Johnson: 2 open now, 2 under way, 1 of them phase 3. Of 203 finished, 57 (28%) have results posted.
Among the 206 studies in Schizophrenia by Johnson & Johnson, this one is the 107th largest by enrollment of the 176 interventional ones that give a count, is one of 3 that started in 2021, is one of 47 in phase 4, and was the 202nd registered.
Johnson & Johnson’s Schizophrenia studies by the year they started, since 1996.
2 of the studies testing risperidone in Schizophrenia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06482554Phase 3Louisiana State University Health Sciences Center ShreveportLumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms. | 2026-12 |
| NCT04478838Centre for Addiction and Mental Health"Extended" (Alternate Day) Antipsychotic Dosing | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 127 studies testing risperidone in Schizophrenia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Johnson & Johnson’s 206 in Schizophrenia:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the long-term symptomatic response (Visit 2 [Week 1] to Visit 14/Week 66 [End of Study {EOS}]) measured by change in the Clinical Global Impressions -Severity for Schizophrenia (CGI-SS) in participants with schizophrenia who are treated in Rwandan real-world healthcare settings with the antipsychotic regimen that starts with oral anti-psychotic (AP) formulation followed by continued treatment with (paliperidone palmitate 1-month [PP1M] and 3-month [PP3M] formulations).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in Observation Phase will receive their treatment prescribed by treating physicians as part of their routine clinical practice and the standard of care (SoC) treatment for Rwanda mental healthcare settings. Participants who have not received risperidone or paliperidone or paliperidone palmitate earlier in Observation Phase will receive oral risperidone 3 milligram (mg) tablets once daily for 3 days in Run-in Phase to determine tolerability. Participants will receive flexible dose range from 50 to 150 mg equivalent (eq.) long acting formulation of paliperidone palmitate once monthly (PP1M) as an intramuscular (IM) injection in Lead-in Treatment Phase for at least 17 weeks (maximum 25 weeks) and if stable dose is achieved for PP1M, participants will enter Maintenance Treatment Phase and continue to receive flexible dose range from 175 to 525 mg eq. long acting formulation of paliperidone palmitate every 3 months (PP3M) as an IM injection for up to 24 weeks.
Drug: Risperidone 3 mg · Drug: Paliperidone Palmitate 50 mg eq. · Drug: Paliperidone Palmitate 75 mg eq. · Drug: Paliperidone Palmitate 100 mg eq. · Drug: Paliperidone Palmitate 150 mg eq. · Drug: Paliperidone Palmitate 175 mg eq. · Drug: Paliperidone Palmitate 263 mg eq. · Drug: Paliperidone Palmitate 350 mg eq. · Drug: Paliperidone Palmitate 525 mg eq.
Participants will receive 3 mg oral risperidone tablet once daily for 3 days.
Participants will receive 50 mg eq. PP1M IM injection for at least 17 weeks (maximum 25 weeks).
Also known as: R092670
Participants will receive 75 mg eq. PP1M IM injection for at least 17 weeks.
Also known as: R092670
Participants will receive 100 mg eq. PP1M IM injection for at least 17 weeks.
Also known as: R092670
Participants will receive 150 mg eq. PP1M IM injection for at least 17 weeks.
Also known as: R092670
Participants will receive 175 mg eq. PP3M IM injection up to 24 weeks.
Also known as: R092670
Participants will receive 263 mg eq. PP3M IM injection up to 24 weeks.
Also known as: R092670
Participants will receive 350 mg eq. PP3M IM injection up to 24 weeks.
Also known as: R092670
Participants will receive 525 mg eq. PP3M IM injection up to 24 weeks.
Also known as: R092670
Mean Change in Clinical Global Impression Severity of Schizophrenia (CGI-SS) Score from Visit 2 (Week 1) to Visit 14 (Week 66 [End of Study {EOS}])
The CGI-SS will be used to provide a clinical measure of the severity of schizophrenia. It is a single-item Likert scale with a 7-point range (1 indicates none to 7 indicates extreme symptoms).
Time frame: Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])
Mean Change in CGI-SS Score from Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])
The CGI-SS will be used to provide a clinical measure of the severity of schizophrenia. It is a single-item Likert scale with a 7-point range (1 indicates none to 7 indicates extreme symptoms).
Time frame: Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])
Mean Change in CGI-SS Score from Visit 2 (Week 1) to Visit 6 (Week 25)
The CGI-SS will be used to provide a clinical measure of the severity of schizophrenia. It is a single-item Likert scale with a 7-point range (1 indicates none to 7 indicates extreme symptoms).
Time frame: Visit 2 (Week 1) to Visit 6 (Week 25)
Change in Personal and Social Performance (PSP) Scale Score from Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])
The PSP scale assesses the degree of difficulty a participant exhibits over a 7-day period within 4 domains of behavior: a) socially useful activities, b) personal and social relationships, c) self-care, and d) disturbing and aggressive behavior. The impairment of each domain is rated on a 6-point basis, including absent (0), mild (1), moderate (2), marked (3), severe (4), and very severe (5). The higher domain score, therefore, indicates, worse functioning in that area.
Time frame: Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])
Change in PSP Scale Scores from Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])
The PSP scale assesses the degree of difficulty a participant exhibits over a 7-day period within 4 domains of behavior: a) socially useful activities, b) personal and social relationships, c) self-care, and d) disturbing and aggressive behavior. The impairment of each domain is rated on a 6-point basis, including absent (0), mild (1), moderate (2), marked (3), severe (4), and very severe (5). The higher domain score, therefore, indicates, worse functioning in that area.
Time frame: Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])
Change in PSP Scale Score from Visit 2 (Week 1) to Visit 6 (Week 25)
The PSP scale assesses the degree of difficulty a participant exhibits over a 7-day period within 4 domains of behavior: a) socially useful activities, b) personal and social relationships, c) self-care, and d) disturbing and aggressive behavior. The impairment of each domain is rated on a 6-point basis, including absent (0), mild (1), moderate (2), marked (3), severe (4), and very severe (5). The higher domain score, therefore, indicates, worse functioning in that area.
Time frame: Visit 2 (Week 1) to Visit 6 (Week 25)
Change in Patient Satisfaction Rating Scale Score from Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])
The patient satisfaction rating is a 4-item scale. Two items use a Likert scale with a 6-point range (0 \[very dissatisfied\] to 5 \[very satisfied\]) and 2 items are multiple-choice (example, "select all that apply"). Higher score indicates greater satisfaction.
Time frame: Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])
Change in Patient Satisfaction Rating Scale Score from Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])
The patient satisfaction rating is a 4-item scale. Two items use a Likert scale with a 6-point range (0 \[very dissatisfied\] to 5 \[very satisfied\]) and 2 items are multiple-choice (example, "select all that apply"). Higher score indicates greater satisfaction.
Time frame: Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])
Change in Patient Satisfaction Rating Scale Score from Visit 2 (Week 1) to Visit 6 (Week 25)
The patient satisfaction rating is a 4-item scale. Two items use a Likert scale with a 6-point range (0 \[very dissatisfied\] to 5 \[very satisfied\]) and 2 items are multiple-choice (example, "select all that apply"). Higher score indicates greater satisfaction.
Time frame: Visit 2 (Week 1) to Visit 6 (Week 25)
Change in Clinician Satisfaction Rating Scale Score from Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])
The clinician satisfaction rating is a 4-item scale. Two items use a Likert scale with a 6-point range (0 \[very dissatisfied\] to 5 \[very satisfied\]) and 2 items are multiple-choice (example, "select all that apply"). Higher score indicates greater satisfaction.
Time frame: Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])
Change in Clinician Satisfaction Rating Scale Score from Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])
The clinician satisfaction rating is a 4-item scale. Two items use a Likert scale with a 6-point range (0 \[very dissatisfied\] to 5 \[very satisfied\]) and 2 items are multiple-choice (example, "select all that apply"). Higher score indicates greater satisfaction.
Time frame: Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])
Change in Clinician Satisfaction Rating Scale Score from Visit 2 (Week 1) to Visit 6 (Week 25)
The clinician satisfaction rating is a 4-item scale. Two items use a Likert scale with a 6-point range (0 \[very dissatisfied\] to 5 \[very satisfied\]) and 2 items are multiple-choice (example, "select all that apply"). Higher score indicates greater satisfaction.
Time frame: Visit 2 (Week 1) to Visit 6 (Week 25)
Change in Schizophrenia Quality of Life Scale (SQLS) Score from Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])
The SQLS has 33 items covering topics such as psychosocial feelings and vitality. Response options are never, rarely, sometimes, often, or always. Scoring algorithms yield a 0 to 100 scale, with higher scores indicating lower quality of life.
Time frame: Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])
Change in SQLS Score from Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])
The SQLS has 33 items covering topics such as psychosocial feelings and vitality. Response options are never, rarely, sometimes, often, or always. Scoring algorithms yield a 0 to 100 scale, with higher scores indicating lower quality of life.
Time frame: Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])
Change in SQLS Score from Visit 2 (Week 1) to Visit 6 (Week 25)
The SQLS has 33 items covering topics such as psychosocial feelings and vitality. Response options are never, rarely, sometimes, often, or always. Scoring algorithms yield a 0 to 100 scale, with higher scores indicating lower quality of life.
Time frame: Visit 2 (Week 1) to Visit 6 (Week 25)
Number of Participants with Treatment-emergent Adverse Events
An adverse event is any untoward medical occurrence in a clinical study participants administered a medicinal (investigational or non-investigational) product. An adverse event does not necessarily have a causal relationship with the intervention. Treatment-emergent adverse events are adverse events with onset after the initiation of treatment in observation phase and separately for initiation of paliperidone palmitate (PP) in Lead-in phase or that are a consequence of a pre-existing condition that has worsened after each treatment phase starts.
Time frame: Up to Week 66
Number of Participants with Abnormalities in Clinical Laboratory Measures
Number of participants with abnormalities in clinical laboratory measures (including serum chemistry, hematology and urinalysis) will be reported.
Time frame: Up to Week 66
Number of Participants with Abnormalities in Vital Signs
Number of participants with abnormalities in vital signs (temperature \[oral\], pulse/heart rate, and blood pressure) will be reported.
Time frame: Up to Week 66
Number of Participants with Abnormalities in Electrocardiogram (ECG)
Number of participants with abnormalities in ECG will be reported.
Time frame: Up to Week 66
Number of Participants with Abnormalities in Physical Examination
Number of participants with abnormalities in physical examination (including body weight, waist circumference, and height) will be reported.
Time frame: Up to Week 66
Number of Participants With Pregnancy Outcome as a Safety Measure
Number of participants with pregnancy outcome will be reported.
Time frame: Up to Week 66
Number of Participants With Suicidal Ideation and Behavior as Assessed by Columbia Suicide Severity Rating Scale (C-SSRS) Score
C-SSRS is an approved and standardized scale for the assessment of the severity of suicidality, through clinical interview. The maximum score assigned for each participant will be summarized into one of three categories: no suicidal ideation or behavior (0), suicidal ideation (1-5), suicidal behavior (6-10). Total score ranges from 1 to 10. Higher scores indicate greater severity. Number of participants with suicidal ideation and behavior will be reported.
Time frame: Visit 12 (Week 46) to Visit 14 (Week 66 [EOS])
Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Data sharing details ↗ · www.janssen.com
No publications or documents are linked to this record.
Ran from Jul 2021 to primary completion in Apr 2024, 32 months.
Of 88 phase 4 interventional studies under Schizophrenia, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 63. This study's 32 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Risperidone · Paliperidone
Janssen-Cilag International NV →